- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made).
1.—(1) The bodies specified in column 1 of Table 1, being bodies appearing to the Secretary of State to represent UK producers, are prescribed for the purposes of section 264B(1)(k) of the 2006 Act.
(2) The purpose for which a body specified in column 1 of Table 1 may use confidential or commercially sensitive information disclosed to it under section 264B(1) of the 2006 Act is the purpose prescribed in the corresponding entry in column 2 of that Table.
Column 1 – Bodies | Column 2 – The purpose for which information disclosed under section 264B(1) of the 2006 Act may be used |
---|---|
Association of British Healthcare Industries; Association of Pharmaceutical Specials Manufacturers; British Association of European Pharmaceutical Distributors; British Generic Manufacturers Association; British Healthcare Trades Association; British In Vitro Diagnostics Association; Healthcare Distribution Association; NHS Pharmacy Production Committee; NHS Pharmaceutical Quality Assurance; Proprietary Association of Great Britain; Surgical Dressings Manufacturers Association Committee; Urology Trade Association. | The purpose is that of exercising functions connected with any of the matters specified in section 264A(3)(a) to (l). |
Association of Independent Multiple Pharmacies; Company Chemists’ Association; National Pharmacy Association. | The purpose is that of exercising functions connected with any of the matters specified in section 264A(3)(a) to (k). |
BioIndustry Association; Ethical Medicines Industry Group. | The purpose is that of exercising functions connected with any of the matters specified in section 264A(3)(c), (e), (g), (i), (l) and (m). |
Association of the British Pharmaceutical Industry | The purpose is that of exercising functions connected with any of the matters specified in section 264A(3)(c), (e), (g), (i) and (k) to (m). |
British Medical Association; Dispensing Doctor’s Association. | The purpose is that of exercising functions connected with any of the matters specified in section 264A(3)(a), (c), (d), (f), (g) and (i) to (k). |
Pharmaceutical Services Negotiating Committee | The purpose is that of exercising functions connected with any of the matters specified in section 264A(3)(b) and (c). |
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: